AbbVie invests $217m to modernise Puerto Rico biologics manufacturing campus
Posted on November 19, 2026
AbbVie will invest $217 million to modernise its biologics manufacturing campus in Barceloneta, Puerto Rico, expanding the company’s production capabilities for immunology and neuroscience medicines.
The project will integrate advanced manufacturing technologies and artificial intelligence into the site to support production of AbbVie’s existing and next-generation treatments.
Work on the modernisation programme is expected to begin in 2026, with the upgraded facility anticipated to be fully operational by 2030.
AbbVie also plans to create 100 new jobs in Puerto Rico as part of the investment.
The positions will include engineers, scientists, manufacturing operators and laboratory technicians.
Azita Saleki, PhD, Executive Vice President and Chief Operations Officer at AbbVie, said the investment reflects the company’s long-term commitment to Puerto Rico and its efforts to strengthen the reliability and capabilities of its U.S. manufacturing network.
AbbVie currently employs more than 1,200 people in Puerto Rico.
Across the U.S. and Puerto Rico, the company employs approximately 29,000 people, including more than 6,000 employees working at domestic manufacturing facilities.
The Barceloneta investment forms part of AbbVie’s previously announced commitment to invest $100 billion in U.S. research and development and capital projects, including manufacturing, over the next decade.
Puerto Rico Governor Jenniffer González Colón said the investment demonstrates the island’s ability to attract and retain high-value biopharmaceutical manufacturing operations.
She added that the project will expand AbbVie’s existing presence while creating additional employment opportunities.
Over the past 16 months, AbbVie has announced more than $2.4 billion in U.S. manufacturing investments that are expected to create more than 1,400 jobs.
These projects include manufacturing investments and expansions in North Carolina, Arizona, Massachusetts, Illinois and Puerto Rico.
The company said the latest modernisation will strengthen its manufacturing infrastructure while supporting a consistent supply of biologic medicines for patients.
Related Topics and Keywords
AbbVie, advanced manufacturing, AI, Artificial intelligence, Barceloneta, Biologics manufacturing, Biopharma, biopharmaceutical manufacturing, Biotechnology, capital investment, Immunology, job creation, manufacturing investment, neuroscience, pharma news, Pharmaceutical Manufacturing, production capacity, Puerto Rico, Supply Chain, U.S. manufacturing
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy















